References
- Bourla, A. (2020), “An Open Letter from Pfizer Chairman and CEO Albert Bourla,” Pfizer investor news Open letter. Available at https://www.pfizer.com/news/hot-topics/an_open_letter_from_pfizer_chairman_and_ceo_albert_bourla.
- CNN (2020), “Dow Soars more than 800 Points after Pfizer Announces Great News About its Vaccine and Joe Biden Declared Victorious,” November 9, 2020. Accessed November 9, 2021. Available at https://www.cnn.com/2020/11/09/investing/dow-stock-market-today/index.html.
- EMA (2005), “Guideline On Data Monitoring Committees,” Accessed November 1, 2021. Available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-monitoring-committees_en.pdf.
- FDA (2006), “Establishment and Operation of Clinical Trial Data Monitoring Committees,” March 2006. Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishment-and-operation-clinical-trial-data-monitoring-committees.
- Hansen, J. (2021), “Data and Safety Review Board Reports How it Monitored the COVID-19 Vaccine Trials,” University of Alabama, June 15, 2021. Accessed December 1, 2021. Available at https://www.uab.edu/news/research/item/12106-data-and-safety-review-board-reports-how-it-monitored-the-covid-19-vaccine-trials.
- Joffe, S., Babiker, A., Ellenberg, S. S., Fix, A., Griffin, M. R., Hunsberger, S., Kalil, J., Levine, M. M., Makgoba, M. W., Moore, R. H., Tsiatis, A. A., and Whitley, R. (2021), “Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials,” The Journal of Infectious Diseases, 224, 1995–2000. https://doi.org/10.1093/infdis/jiab263.
- Merck Investor News (2021), “Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study,” October 1, 2021 6:00 am ET. Available at https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/.
- Newsom, G. (2020), “Governor Newsom Names Scientific Safety Review Workgroup to Advise State on COVID-19 Vaccines,” October 10, 2020. Accessed November 1, 2021. Available at https://www.gov.ca.gov/2020/10/19/governor-newsom-names-scientific-safety-review-workgroup-to-advise-state-on-covid-19-vaccines/.
- Pradhan, R. (2020a), “Secret, Powerful Panels will Pick Covid-19 Vaccine Winners,” NBC News, September 24, 2020. Available at https://www.nbcnews.com/health/health-news/secret-powerful-panels-will-pick-covid-19-vaccine-winners-n1240885; https://khn.org/news/these-secret-safety-panels-will-pick-the-covid-vaccine-winners/.
- Pradhan, R. (2020b), “These Secret Safety Panels Will Pick the COVID Vaccine Winners,” Sept 24, 2020, KHN, Kaiser Family Foundation. Accessed November 1, 2021. Available at https://khn.org/news/these-secret-safety-panels-will-pick-the-covid-vaccine-winners/.
- Reuters (2020), “Pfizer CEO: We Didn’t Delay Vaccine Results Until after Election,” November 17, 2020. Available at https://mobile.reuters.com/article/amp/idUSKBN27X2N3.
- Thomas, K. (2020), “All Eyes Are on Pfizer as Trump Pushes for Vaccine by October,” New York Times, September 30, 2020. Accessed November 9, 2021. Available at https://www.nytimes.com/2020/09/30/health/pfizer-covid-vaccine.html.
- WHO (2005), “Operational Guidelines for the Establishment and Functioning of Data and Safety Monitoring Boards,” WHO reference number: TDR/GEN/Guidelines/05.1. Available at https://www.who.int/tdr/publications/tdr-research-publications/operational-guidelines/en/.